Status: Recruiting
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 19-64Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Jul 10, 2025Locations: 1
Eligibility criteria
Healthy adults aged 19 to 64 years old as of the date of written consent. [+1]
Individuals who have received a vaccine within 4 weeks prior to administration o... [+3]